source
- Lancet study assesses performance of Google’s diagnostic chatbot AMIESTAT’s Health Tech newsletter highlighted a recent evaluation of Google’s diagnostic chatbot AMIE that was published in The Lancet. The article notes that the study examined how well the chatbot c…
- Nurix halts development of BTK degrader zelebrudomide after phase 1 reviewNurix announced it will discontinue clinical development of its BTK degrader zelebrudomide, also known as NX-2127, following completion of enrollment in a phase 1 trial for aggressive non‑Hodgkin l…